---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-012058"
form_type: "8-K"
ticker: "RNXT"
cik: "0001574094"
company_name: "RenovoRx, Inc."
filed_at: "2026-03-23T23:59:59+00:00"
generated_at: "2026-05-15T09:22:05.501059+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# RenovoRx raises $10M via common stock and milestone warrants in oversubscribed offering

## Summary
- Raised ~$10M gross from sale of 8.4M shares, 2.2M pre-funded warrants, and 5.3M milestone warrants to 15 investors (including insiders).
- Milestone warrants (50% coverage) expire upon $1.5M quarterly product revenue or Mar 30, 2029; exercise price $1.751 (institutional), $1.933 (insiders).
- Proceeds to boost RenovoCath commercial rollout and fund Phase III TIGeR-PaC trial to full enrollment by mid-2026.
- Insider participation at $1.0288/share vs $0.938 for institutions to comply with Nasdaq pricing rules.
- Company must file resale registration within 30 days; liquidated damages of up to 10% of subscription amount if delayed.

## SEC filing metadata
- accession: 0001493152-26-012058
- form_type: 8-K
- ticker: RNXT
- cik: 0001574094
- company_name: RenovoRx, Inc.
- filed_at: 2026-03-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574094/000149315226012058/0001493152-26-012058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574094/000149315226012058/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-012058
- JSON: https://secwatch.observer/filing/0001493152-26-012058.json
- Plain text: https://secwatch.observer/filing/0001493152-26-012058.txt

## Key facts
- Material Agreements
  RenovoRx, Inc. entered into Securities Purchase Agreement with 15 accredited investors or qualified institutional buyers valued at aggregate gross proceeds of approximately $10 million (effective 2026-03-17).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: 15 accredited investors or qualified institutional buyers
  - Value: aggregate gross proceeds of approximately $10 million
  - Effective: 2026-03-17
  source text: On March 17, 2026, RenovoRx, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) in connection with a private placement offering by the Company (the “Offering”) to 15 accredited investors or qualified institutional buyers (the “Investors”), five of whom are directors, officers or employees of the Company (the “Insiders”) and the remaining are non-affiliated institutional investors (the “Institutional Investors”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1574094/000149315226012058/0001493152-26-012058-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.